What is the role of upfront addition of an ALK inhibitor in an ALK positive mature B Cell lymphoma in an AYA patient?

Crizotinib has gained FDA approval in pediatric patients > 1 as monotherapy for relapsed anaplastic large cell lymphoma (ALK+) based on the COG ADVL0912 study. The agent was subsequently studied in upfront ALCL with aggressive chemotherapy based on the European ALCL99 regimen in ANHL12P1 but there were significant thrombosis concerns encountered in the study. There is not data that I am aware of for upfront therapy in AYA ALK + mature B NHL but it certainly makes sense based on the poor outcomes of this rare entity with CHOP based chemotherapy. I have personally treated an 18-year-old man with large erosive mediastinal OCT-2/BOB-1/ALK + mature B cell lymphoma with the COG ANHL12P1 regimen with crizotinib with rivaroxaban prophylaxis with go...